BAY-876

solute carrier family 2 member 1 ; Homo sapiens







7 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35247917 Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells. 2022 May 4 2
2 34869036 A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma. 2021 1
3 34906161 TRIM38 triggers the uniquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer. 2021 Dec 14 1
4 32826891 GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. 2020 Aug 21 1
5 30861255 Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer. 2019 May 1
6 30602670 Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876. 2018 Dec 31 5
7 27552707 Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876. 2016 Oct 19 1